Salvatore Russo, Sara Feola, Michaela Feodoroff, Jacopo Chiaro, Gabriella Antignani, Manlio Fusciello, Federica D'Alessio, Firas Hamdan, Teijo Pellinen, Riikka Mölsä, Lorella Tripodi, Lucio Pastore, Mikaela Grönholm, Vincenzo Cerullo
Cancer immunotherapy requires a specific antitumor CD8+ T cell-driven immune response; however, upon genetic and epigenetic alterations of the antigen processing and presenting components, cancer cells escape the CD8+ T cell recognition. As a result, poorly immunogenic tumors are refractory to conventional immunotherapy. In this context, the use of viral cancer vaccines in combination with hypomethylating agents represents a promising strategy to prevent cancer from escaping immune system recognition...
March 21, 2024: Mol Ther Oncol